

AD \_\_\_\_\_

Award Number: DAMD17-99-2-9027

TITLE: Drug Development and Conservation of Biodiversity in West and Central Africa

PRINCIPAL INVESTIGATOR: Cyrus J. Bacchi, Ph.D.

CONTRACTING ORGANIZATION: Pace University  
New York, New York 10038-1502

REPORT DATE: May 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE May 2002	3. REPORT TYPE AND DATES COVERED Annual (1 May 01 - 30 Apr 02)
----------------------------------	----------------------------	---

4. TITLE AND SUBTITLE Drug Development and Conservation of Biodiversity in West and Central Africa	5. FUNDING NUMBERS DAMD17-99-2-9027
---	--

6. AUTHOR(S)  
Cyrus J. Bacchi, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  
Pace University  
New York, New York 10038-1502  
  
cbacchi@pace.edu

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

20020930 059

12a. DISTRIBUTION / AVAILABILITY STATEMENT  
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

**13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information)**  
This project is being conducted as part of Associated Project #3 of the International Cooperative Biodiversity Group Program under the direction of the Walter Reed Army Institute for Research. The focus of this ICBG Program's study is plants of West and Central Africa. During the reporting period, a total of 41 plant extracts were received from WRAIR, an additional eight compounds were received from the University of Dschang (Cameroon, AP#2). These agents were tested *in vitro* vs. strains of African trypanosomes (*Trypanosoma brucei* group) and of pathogenic trichomonads (*Trichomonas vaginalis* and *Trichomonas foetus*). An additional 68 extracts were received from WRAIR in late February and are now entering preliminary screening.  
For the trypanosome screens, 39 of 41 WRAIR extracts and all eight of the AP #2 extracts were tested *in vitro* vs. three strains. Eight extracts were tested vs. two strains of *T. vaginalis* and 22 were tested vs. *T. foetus*. For trypanosome studies, 21 of the WRAIR extracts and 4 of 8 of the AP#2 extracts had IC<sub>50</sub> values ≤20 µg/ml. Three of the extracts tested vs *T. vaginalis* had minimal inhibitory concentrations of 0.3–0.6 mg/ml, while 2 of 22 tested vs. *T. foetus* had similarly high activity. Extracts active vs. trypanosomes were tested in a mouse model infection of *T. brucei* at a dose range of 1–25 mg/kg i.p for three days. None of the 21 extracts tested were curative, however, two prolonged life. Some of the plant genera showing activity *in vitro* were: *Fromomum*, *Aspilia*, *Chamaecrista*, *Cryptolepis*, *Enantia*, *Hoshundia*, *Icacina*, *Uvaria*, and *Pleiocarpa*.

14. SUBJECT TERMS  
Drug Development

15. NUMBER OF PAGES  
19  
16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT  
Unclassified  
Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE  
Unclassified  
Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT  
Unclassified

20. LIMITATION OF ABSTRACT  
Unlimited

## Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	7-8
References.....	8
Appendices.....	9-19

## I. Introduction

This project is Associated Project #3 of the International Cooperative Biodiversity Group (ICBG) which concerns the activities of plant extracts from Central and West Africa on growth of African trypanosomes and pathogenic trichomonads. The African trypanosomes include *Trypanosoma brucei* (veterinary parasite) and *Trypanosoma rhodesiense* (human and veterinary parasite) and the trichomonads include *Trichomonas vaginalis* (human parasite) and *Tritrichomonas foetus* (veterinary parasite).

The past several years have seen an explosion in the number of cases of African sleeping sickness, from an estimated 25,000 cases/year to  $\geq 500,000$  cases/year (WHO 2001), while human trichomoniasis remains a major STD in the United States and throughout the world (Lossik, 1990). Veterinary diseases caused by both groups of parasites continue to inflict economic tolls on farmers and herdsman. No new readily available drugs have been developed in  $> 50$  years for African sleeping sickness, while pentamidine and the arsenical melarsoprol remain the mainstays for treatment. There is significant evidence of neurotoxicity and fatalities due to the latter agent (Burri and Keiser, 2002; Keiser et al., 2001; Legros and Evans, 1999). Chemotherapy of human trichomoniasis relies solely on metronidazole, developed in the 1950's, while there is no treatment for veterinary trichomoniasis (Yule et al., 1989). With drugs in common use for so long, it is inevitable that resistance develop (Keiser et al., 2001), thus making it important to search for new, effective chemotherapeutic agents.

This project is being conducted as part of Associated Project #3 of the International Cooperative Biodiversity Group (ICBG) Program under the direction of the Walter Reed Army Institute for Research (WRAIR). The focus of this ICBG Program's study is plants of West and Central Africa. During the reporting period, a total of 41 plant extracts were received from WRAIR, and an additional 8 compounds were received from the University of Dschang (Cameroon, AP #2). These agents were tested *in vitro* vs. strains of African trypanosomes (*Trypanosoma brucei* group) and of pathogenic trichomonads (*Trichomonas vaginalis* and *Tritrichomonas foetus*). An additional 68 extracts were received from WRAIR in late February and these are entering preliminary screening at this time.

For the trypanosome screens, 39 of 41 WRAIR extracts and all 8 of the AP #2 extracts were tested *in vitro* vs. three strains. Eight extracts were tested vs. two strains of *T. vaginalis* and 22 were tested vs. *T. foetus*. For trypanosome studies, 21 of the WRAIR extracts and 4 of 8 of the AP #2 extracts had  $IC_{50}$  values  $\leq 20$   $\mu\text{g/ml}$ . Three of the extracts tested vs. *T. vaginalis* had minimal inhibitory concentrations (MIC) of 0.3–0.6 mg/ml, while 2 of 22 tested vs. *T. foetus* had similarly high activity. Extracts active vs. trypanosomes were tested in a mouse model infection of *T. brucei* at a dose range of 1–25 mg/kg i.p for three days. None of the 21 extracts tested were curative, however, two prolonged the life of infected animals. Some of the plant genera showing activity *in vitro* were: *Afromomum*, *Aspilia*, *Chamaecrista*, *Cryptolepis*, *Enantia*, *Hoslundia*, *Icacina*, and *Pleiocarpa*; the two extracts active in the trypanosome model infection were from *Icacina trichanta* and *Uvaria chamae*.

## II. Body

a) African trypanosomes. *In vitro* screens with bloodstream form trypanosomes are set up in 24 well plates using duplicate wells of four extract concentrations each (in HMI medium) plus full-growth controls, as detailed in Bacchi et al. (1998). Initial wide concentration curves were followed by narrow-ranging curves to determine IC<sub>50</sub> values. Strains of trypanosomes used were: *Trypanosoma brucei*, Lab 110 EATRO (veterinary parasite); *Trypanosoma rhodesiense* KETRI 243 (human isolate), *T. rhodesiense* 243As 10-3 (clone of KETRI 243 highly resistant to melarsoprol and pentamidine).

b) Trichomonads. The method used was the minimal inhibitory concentration (MIC) assay developed by Meingassner et al. (1978). Strains used were *T. vaginalis* C1-NIH (ATTC 30001) and a metronidazole-resistant strain, CDC-085 (ATCC 50143). These are incubated aerobically in 96 well plates with triplicate serial dilutions of each extract, and checked at 24 and 48 h.

c) In vivo studies. For African trypanosomes, extracts having IC<sub>50</sub> values of  $\leq 20$   $\mu\text{g/ml}$  were tested in a *T. brucei* Lab 110 EATRO mouse model infection (Bacchi et al., 1990). Mice (10–25 g) were infected with  $5 \times 10^5$  trypanosomes and treatment was begun 24 h later. Since all extracts were solubilized in 50% DMSO, extracts were diluted in this solvent to achieve correct concentrations. Mice were dosed once daily for three days, by the intraperitoneal route. Animals surviving  $> 30$  days with no evidence of parasites in blood smears are considered cured.

### Results

a) African trypanosomes. *In vitro* screening of plant extracts is conducted using bloodstream forms of three isolates: *Trypanosoma brucei* Lab 110 EATRO (veterinary parasite), *Trypanosoma rhodesiense*, KETRI 243, KETRI 243As10-3 (human pathogens). The latter strain is highly melarsoprol resistant and has moderate resistance to pentamidine (Bacchi et al., 1990). The culture methods have been described (Bacchi et al., 1998), and involve culture in 24 well plates (37°C, 5% CO<sub>2</sub>) using the medium of Hirumi et al. (1989). Plant extracts are dissolved in 100% DMSO (50 mg/ml stock) and diluted with medium. Trypanosomes are cultured for 72 h. in the presence of extract, with one-half the volume of each well replaced daily with fresh medium + plant extracts. Cell counts are made (Coulter Counter, Model Z1) at 48 and 72 h, with data from 48 h. generally used. Control cell counts were  $5 \times 10^6/\text{ml}$  at 48 h. Initially a broad concentration curve is used, followed by a close-ranging curve to establish IC<sub>50</sub> values. All curves are done in duplicate, with the results expressed as IC<sub>50</sub> ( $\mu\text{g}$  extract/ml medium).

A total of 39 out of 41 extracts received from Dr. Chris Okunji of WRAIR on March 27, 2000 (Table 1), and 8 received from Drs Appollinaire Tsopmo and Pierre Tane of the University of Dschang (Cameroon - AP #2) were tested. Two of the WRAIR extracts were insoluble in 100% DMSO and were not tested. The 39 WRAIR extracts were tested vs. the three trypanosome isolates; 19 of 39 isolates tested had IC<sub>50</sub> values of  $\leq 20$   $\mu\text{g/ml}$ , with 4 having values of  $\leq 1$   $\mu\text{g/ml}$  (Table 2). Of the AP #2 (Cameroon) extracts 5 of 8 had IC<sub>50</sub> values of  $\leq 20$   $\mu\text{g/ml}$  (Table 3).

We tested 16 of the most active WRAIR extracts in a mouse model infection using *T. brucei* Lab 110 EATRO (Bacchi et al., 1998). Mice (25–30 g) were infected with  $5 \times 10^5$  trypanosomes and the infection allowed to develop for 24 h. Plant extracts were diluted to 5 mg/ml with 50%

DMSO. Mice (groups of 3) were injected i.p. with 1, 5, 10 or 25 mg/kg extract once daily for three days. Doses higher than 25 mg/kg were not possible, since they would increase the volume of DMSO to a toxic level. In each experiment, three mice served as infected, untreated controls. Control mice died at four days, with the life-span of treated mice compared to that of controls. None of these extracts were curative, although #1876 (*Ipacina trichanta*, aq.) and #1891 (*Uvaria chamae*, CH<sub>2</sub> Cl<sub>2</sub>) extended the life-span of mice 2–3 days in animals receiving 10 or 25 mg/kg (Table 4). Extract #1889 (*Uvaria chamae*, CH<sub>2</sub> Cl<sub>2</sub>) was highly toxic, with animals receiving 5 mg/kg dose dying within 24 h. of the initial dose. It would be valuable to further purify #1876 and #1891 to find a more active component. Extract #1891 is especially interesting since a separate CH<sub>2</sub> Cl<sub>2</sub> extract of *U. chamae* proved highly toxic (#1889) at the same dose levels. Methanol extracts of *U. chamae* (#1890) proved less effective *in vitro* than #1889 and 1891 and were inactive *in vivo*, as was aqueous an extract (#1898).

In late February 2002, WRAIR sent an additional 68 new plant extracts, containing 25 mg/sample. These are #s SU 2140–2181, 2192, 2194–2220. Screening studies have begun on SU 2140–2170, with initial growth curve screens done vs. the *T. brucei* isolate (Table 5). Eleven extracts gave IC<sub>50</sub> values < 10 µg/ml: SU 2140, *Premna quadrifolia*; 2145, *Cassia siama*; 2148, *Guarea thompsonii*; 2156, *Goyania long pelara*; 2157, *Culcasis scanders*; 2158–9, *Hyptis suaveolens*; 2162, *Cassytha filiformis*; 2164–65, *Holarrhena floribunda*; 2166, *Jatropha curcas*.

b) Pathogenic trichomonads. *In vitro* screening of extracts was done using three isolates: *Trichomonas vaginalis* ATCC 3001 (metronidazole sensitive); *T. vaginalis* ATCC 50143 (metronidazole resistant); *Tritrichomonas foetus* KV1. The growth assessment method used was the minimal inhibitory concentration (MIC) assay of Mengassner et al. (1978). The organisms are grown in 96 well microliter plates with 200 µl of medium/well. Drug dilutions are made serially (duplicate sets) to give final concentrations of 400–0.78 mg/ml. After 48 h. plates are read by microscope and each well is scored on the basis of motility and growth, with a 4 representing full growth and 0 being no growth and total loss of motility. The lowest concentration producing a 0 in duplicate wells is the MIC.

A total of eight extracts were tested against metronidazole-sensitive (ATCC 30001) and -resistant (ATCC 50143) strains of *T. vaginalis* (Table 6). Two extracts (#1863 and #1868) had MIC values ≤ 0.6 mg/ml for the sensitive isolate and four had values of ≤ 0.6 mg/ml for the resistant isolate. The active extracts were from *Aspilia africana* (#1863, CH<sub>3</sub> Cl<sub>2</sub>), *Combretum dulchipetalum* (#1868, Me OH; #1870, aq.), *Enantia chlorontha* (#1873, Me OH), *Mormodica charanta*, CH<sub>2</sub>Cl<sub>2</sub>). In particular, the aqueous extract of *Combretum* (#1870) was highly effective vs. the metronidazole-resistant isolate, at a concentration equal to that of metronidazole (0.3 mg/ml vs. 0.4 mg/ml, respectively, Table 6).

A total of 31 extracts were tested vs. *Tritrichomonas foetus* (Table 7). Of these, four (#1874, 1879, 1895, 1896) had MIC values of 0.6 mg/ml. These were from *Hoslundia opposita* (CH<sub>2</sub>Cl<sub>2</sub>), *Phyllanthus amarus* (aq.) and *Cleistopholis patens* (Me OH, CH<sub>2</sub>Cl<sub>2</sub>), and differed in origin from extracts found active vs. *T. vaginalis*.

In all, eight extracts of 31 tested were active vs. the trichomonad group (Table 8). Of these, four were also active vs. African trypanosomes, indicating that this overlap activity may be a function of generalized cytotoxicity.

c) Training. At Haskins Laboratories of Pace University, the function of our group, in part, is to train undergraduates. This past reporting period, a total of four Pace students worked on various phases of the ICBG project. In addition, an NSF High School Science Teacher Summer Training Institute is held annually at the University (July 23–August 3, 2001). This two week program features the ecosystem as a major topic, and the teachers are given lectures on the meaning of biodiversity including the activities of the ICBG program, and a tour of laboratory facilities. Our group is also working with phytochemists at WRAIR and the University of Dschang towards finalizing several papers for publication.

The only issue of concern is the distribution of plant extracts for use in our sub-project. We would like to see follow-up on certain extracts which seem highly active *in vitro*, for testing *in vivo*, i.e., purification of the active agents in these extracts so that an increase in growth inhibitory activity can be determined, also the possible identification of the chemical nature of the active agent(s).

### III. Key Research Accomplishments

- Identification of 19 WRAIR plant extracts and another 5 from Cameroon (AP #2) out of a total of 47 extracts tested which had IC<sub>50</sub> values of  $\leq 20$   $\mu\text{g/ml}$  for three African trypanosomes isolates.
- Seven of the WRAIR and 2 of the AP #4 extracts had IC<sub>50</sub> values of  $\leq 5$   $\mu\text{g/ml}$  for three African trypanosomes isolates.
- Since the purity and the potency of these extracts is not known with respect to the active agents, we believe the most active of these extracts are candidates for further purification and/or *in vivo* testing vs. African trypanosomes.
- Three of eight extracts tested vs. *T. vaginalis* had MIC values  $\leq 0.6$  mg/ml vs. a metronidazole resistant isolate.
- Four of 31 extracts tested vs. *T. foetus* had MIC values of  $\leq 0.6$  mg/ml
- The most active extracts vs. *T. vaginalis* were not those most active against the African trypanosomes, indicating some degree of specificity is present, with fewer of these active vs. trypanosomes having MIC values in the range of 0.3–0.6 mg/ml.

IV. Reportable Outcomes. None

### V. Conclusions

Recent research has identified a number of plant extracts having significant *in vitro* growth inhibitory activity against African trypanosomes and pathogenic trichomonads. Additional supplies of the extracts are needed to effect extended (5 or 7 day) dosing regimens. Moreover, additional purification of active extracts is needed to allow better control of *in vivo* dosing.

In comparing *in vitro* activities of extracts, it is evident that a degree of specificity was again present – for example, SU-1870 and 1880 were highly effective vs. trypanosomes but not *T. vaginalis* isolates.

Economically, this is an important program for Nigeria and Cameroon: both are endemic for human and veterinary trypanosomiasis, while STD infections, including *T. vaginalis* and bovine trichomoniasis are a significant source of human suffering and an economic drain. There is an urgent need for new and inexpensive drugs for trypanosomiasis. Treatment of human trichomoniasis depends solely on metronidazole, and there is no agent currently available for bovine trichomoniasis [metronidazole kills the microbial flora of the rumen and cannot be given to cattle]. Development of anti-protozoal agents from local plants would be a major factor in the well-being of these populations and a boost to local and national economics.

## VI. References

- Bacchi, C.J., Vargas, M., Rattendi, D., Goldberg, B., Zhou, W. 1998. Antitrypanosomal activity of a new triazine derivative, SIPI 1029, *in vitro* and in model infections. *Antimicrob. Agents Chemother.* 42:2718–2721.
- Bacchi, C.J., Nathan, H.C., Livingston, T., Valladares, G., Saric, M., Sayer, P.D., Njogu, A.R., Clarkson, A.B. Jr. 1990. Differential susceptibility of DL- $\alpha$ -difluoromethylornithine in clinical isolates of *Trypanosoma brucei rhodesiense*. *Antimicrob. Agents Chemother.* 34:1183–1188.
- Burri, C. and Keiser J. 2002. Pharmacokinetic investigation on patients from Northern Angola refractory to melarsoprol treatment. *Trop. Med. Int. Health.* 6: in press.
- Hirumi, H., and Hirumi, K. 1989. Continuous cultivation of *Trypanosoma brucei* bloodstream forms in a medium containing a low concentration of serum protein without feeder cell layers. *J. Parasitol.* 75:985–989.
- Keiser, J., Stich, A., Burri C. 2001. New drugs for the treatment of human African trypanosomiasis, research and development. *Trends in Parasitology.* 17:42–49.
- Legros, D., and Evans, S. 1999. Risk factors for treatment failure after melarsoprol for *Trypanosoma brucei gambiense* trypanosomiasis in Uganda. *Trans. Roy. Soc. Trop. Med. Hyg.* 93:439–442.
- Lossick, J.G. 1990. Therapy of urogenital trichomoniasis. *In: Honigberg, B.M. Trichomonads Parasitic in Humans.* pp. 324–341. Springer-Verlag, NY.
- Meingassner, J.G., Mieth, J., Czok, R., Lindmark, D.G., Muller, M. 1978. Assay conditions and the demonstration of nitroimidazole resistance in *Tritrichomonas foetus*. *Antimicrob. Agents Chmother.* 13:1–3.
- WHO. World Health Organization and Aventis announce a major initiative to step up efforts against sleeping sickness. WHO Press Release 2001, 23.
- Yule, A., Skirron, S.Z., BonDurant, R.H. 1989. Bovine trichomoniasis. *Parasitology Today.* 5:373–377.

**Table 1.** Plant extracts received from WRAIR, March 27, 2000.

<b>Lab Number</b>	<b>Plant Name</b>	<b>Extract</b>	<b>mg</b>
SU 1863	<i>Aspilia africana</i>	CH <sub>2</sub> Cl <sub>2</sub>	50
SU 1864	<i>Cassaytha filifoimis</i>	MeOH	81
SU 1865	<i>Celosia trigyna</i>	MeOH	50
SU 1866	<i>Chamaecrista mimosoides</i>	CH <sub>2</sub> Cl <sub>2</sub>	55
SU 1867	<i>Combretum dulchipetalum</i>	CH <sub>2</sub> Cl <sub>2</sub>	52
SU 1868	<i>Combretum dulchipetalum</i>	MeOH	50
SU 1869	<i>Combretum dulchipetalum</i>	CH <sub>2</sub> Cl <sub>2</sub>	52.7
SU 1870	<i>Combretum dulchipetalum</i>	Aq.	46
SU 1871	<i>Combretum dulchipetalum</i>	Aq.	50
SU 1872	<i>Cryptolepis sanguinolenta</i>	CH <sub>2</sub> Cl <sub>2</sub>	60
SU 1873	<i>Enantia chlorontha</i>	MeOH	52.7
SU 1874	<i>Hoslundia opposita</i>	CH <sub>2</sub> Cl <sub>2</sub>	50
SU 1875	<i>Icacina trichanta</i>	MeOH	50
SU 1876	<i>Icacina trichanta</i>	Aq.	47
SU 1877	<i>Mormodica charanta</i>	CH <sub>2</sub> Cl <sub>2</sub>	62
SU 1878	<i>Phyllanthus amarus</i>	CH <sub>2</sub> Cl <sub>2</sub>	51
SU 1879	<i>Phyllanthus amarus</i>	Aq.	60
SU 1880	<i>Pleiocarpa pycnantha</i>	CH <sub>2</sub> Cl <sub>2</sub>	60
SU 1881	<i>Scoparia dulcis</i>	CH <sub>2</sub> Cl <sub>2</sub>	51
SU 1882	<i>Scoparia dulcis</i>	MeOH	50
SU 1883	<i>Scoparia dulcis</i>	Aq.	50

**Table 1 (continued)**

<b>Lab Number</b>	<b>Plant Name</b>	<b>Extract</b>	<b>mg</b>
SU 1884	<i>Solenostemon monostachyus</i>	CH <sub>2</sub> Cl <sub>2</sub>	48
SU 1885	<i>Solenostemon monostachyus</i>	Aq.	50
SU 1886	<i>Trimfetta tomentosa</i>	CH <sub>2</sub> Cl <sub>2</sub>	55
SU 1887	<i>Trimfetta tomentosa</i>	MeOH	50
SU 1888	<i>Urena lobata</i>	CH <sub>2</sub> Cl <sub>2</sub>	59
SU 1889	<i>Uvaria chamae</i>	CH <sub>2</sub> Cl <sub>2</sub>	59
SU 1890	<i>Uvaria chamae</i>	MeOH	79
SU 1891	<i>Uvaria chamae</i>	CH <sub>2</sub> Cl <sub>2</sub>	89
SU 1892	<i>Uvaria chamae</i>	MeOH	51
SU 1893	<i>Uvaria chamae</i>	CH <sub>2</sub> Cl <sub>2</sub>	58
SU 1894	<i>Uvaria chamae</i>	MeOH	81
SU 1895	<i>Cleistopholis patens</i>	CH <sub>2</sub> Cl <sub>2</sub>	85
SU 1896	<i>Cleistopholis patens</i>	MeOH	58
SU 1897	<i>Crescentia cujete</i>	CH <sub>2</sub> Cl <sub>2</sub>	50
SU 1898	<i>Uvaria chamae</i>	Aq.	54
SU 1899	<i>Uvaria chamae</i>	Aq.	50
SU 1900	BP 16524		40
SU 1901	BP 16533		40
SU 1902	<i>Cleistopholis patens</i>	Aq.	52
SU 1903	<i>Uvaria chamae</i>	Aq.	48

**Table 2.** Activity of WRAIR extracts vs. African trypanosomes *in vitro*: *T. brucei* Lab 110 EATRO; *T. rhodesiense* KETRI 243 and 243 As 10-3.

Extract	IC <sub>50</sub> (µg/ml)		
	EATRO 110	KETRI 243	KETRI 243 As10-3
SU-1863	2.4	20	20.5
SU-1864	71	225	220
SU-1865	82	140	165
SU-1866	6.6	36	25
SU-1867	19.5	54.5	61
SU-1868	11	16	18.5
SU-1869	13.5	11	22
SU-1870	7.3	6.4	6.6
SU-1871	18.5	17.5	22.5
SU-1872	0.66	5.7	4.8
SU-1873	6.9	9.8	8.4
SU-1874	5.0	1.75	28.5
SU-1875	7.65	5.75	6.7
SU-1876	22	15.5	24.5
SU-1877	28.5	59	24.5
SU-1878	0.84	4.6	0.92
SU-1879	12.5	13.5	18.5
SU-1880	0.97	0.69	4.2
SU-1881	17.5	22.5	19.5
SU-1882	205	215	165
SU-1883	71	200	165
SU-1884	63.5	45.5	65

**Table 2** (continued)

Extract	IC <sub>50</sub> (µg/ml)		
	EATRO 110	KETRI 243	KETRI 243 As10-3
SU-1885	205	225	180
SU-1886	64	7.9	135
SU-1887	129	150	160
SU-1888	145	25	185
SU-1889	3.7	36	187.5
SU-1890	22.5	73	14.5
SU-1891	0.57	2.6	33.25
SU-1892	180	190	140
SU-1893	48	21.5	74
SU-1894	20	21.9	16.5
SU-1895	200	64	150
SU-1896	135	175	
SU-1897	125	295	330
SU-1898	28.5	28.5	20.1
SU-1899	94	190	85
SU-1900*	-	-	-
SU-1901*	-	-	-
SU-1902	220	225	160
SU-1903	78	175	125
Pentamidine	0.0008	0.00098	0.00075
Melarsen Oxide	0.0075	0.016	0.016

\*Not soluble in DMSO

**Table 3.** Activity of University of Dschang (AP #2) extracts vs. African trypanosomes *in vitro*.

	IC <sub>50</sub> (µg/ml)		
	Lab110 EATRO	KETRI	
		243	243 As 10-3
ASP	0.5	1.5	3.9
ASS <sub>2</sub>	28	26.5	130
ASS <sub>4</sub>	30.5	16	51
ASS <sub>5</sub>	55	50.1	56
TZM <sub>1A</sub>	21.5	18	15.9
TZM <sub>1</sub>	2.35	22.5	17
TZM <sub>4</sub>	4.45	2.1	1.85
TZM <sub>4</sub> HCl	3.59	3.59	1.80

**Table 4.** WRAIR extracts with highest activity ( $IC_{50} \leq 20 \mu\text{g/ml}$ ) vs. African trypanosomes and tested *in vivo* in a *T. brucei* model.

Lab Number	Plant Name	Extract
*SU 1863	<i>Aspilia africana</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1866	<i>Chamaecrista mimosoides</i>	CH <sub>2</sub> Cl <sub>2</sub>
*SU 1870	<i>Combretum dulchipetalim</i>	Aq.
SU 1872	<i>Cryptolepis sanguinolenta</i>	CH <sub>2</sub> Cl <sub>2</sub>
*SU 1873	<i>Enantia chlorontha</i>	MeOH
*SU 1874	<i>Hoslundia opposita</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1875	<i>Icacina trichanta</i>	MeOH
SU 1878	<i>Phyllanthus amarus</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1880	<i>Pleiocarpa pycnantha</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1886	<i>Trimfetta tomentosa</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1889	<i>Uvaria chamae</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1890	<i>Uvaria chamae</i>	MeOH
SU 1891	<i>Uvaria chamae</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1894	<i>Uvaria chamae</i>	MeOH
SU 1898	<i>Uvaria chamae</i>	aq.
SU 1900	BP 16524	-

\* Also active vs. trichomonads

**Table 5.** Activity of WRAIR extracts, received February 22, 2002 vs. African trypanosomes *in vitro*: *T. b. brucei* Lab 110 EATRO.

Extract	Plant	IC <sub>50</sub> (µg/ml) <i>T. b. brucei</i>
*SU 2140	<i>Premna quadrifolia</i>	2.8
SU 2141	<i>Asystasis gangetica</i>	> 100
SU 2142	<i>Waltheria indica</i> (Stems/Leaves)	25.5
SU 2143	<i>Pupalia lappacea</i>	> 100
SU 2144	<i>Grewia cissiodes</i> (Leaves)	67
*SU 2145	<i>Cassia siamea</i> (leaves/stems) (dry)	6.6
SU 2146	<i>Uvaria chamae</i> (Roots)	28.5
SU 2147	<i>Uvaria chamae</i> (Roots)	> 100
*SU 2148	<i>Guarea thompsonli</i> (Stem bark)	4.0
SU 2149	<i>Guarea thompsonli</i> (Stem bark)	12
SU 2150	<i>Guarea thompsonli</i> (Stem bark)	55
SU 2151	<i>Melian excelsa</i> (Stem bark)	[0.05 - 0.5]
SU 2152	<i>Solenostemon monostachyus</i> (Leaves)	[5 - 50]
SU 2153	<i>Hymenocardia acida</i> (Leaves)	27.5
SU 2154	<i>Aspienium bulbiferum</i> (whole plant)	66

\*Most active - IC<sub>50</sub> < 10 µg/ml.

**Table 5 (continued)**

<b>Extract</b>	<b>Plant</b>	<b>IC<sub>50</sub> (µg/ml) <i>T. b. brucei</i></b>
SU 2155	<i>Asystasia gangetica</i>	9.3
*SU 2156	<i>Goyania long pelara</i> (Leaves/stems)	5.8
*SU 2157	<i>Culcasis scanders</i> (whole plant)	0.235
*SU 2158	<i>Hyptis suaveolens</i> (leaves)	0.10
*SU 2159	<i>Hyptis suaveolens</i> (leaves)	7.5
SU 2160	<i>Picralima nitida</i> (whole plant)	> 100
SU 2161	<i>Picralima nitida</i> (whole plant)	> 100
*SU 2162	<i>Cassytha filiformis</i> (whole plant)	4.6
SU 2163	<i>Cassytha filiformis</i> (whole plant)	5.0
*SU 2164	<i>Holarrhena floribunda</i> (leaves)	0.5
*SU 2165	<i>Holarrhena floribunda</i> (leaves)	3.8
*SU 2166	<i>Jatropha curcas</i> (leaves)	5.0
SU 2167	<i>Jatropha curcas</i> (leaves)	[0.05 - 0.5]
SU 2168	<i>Ritchiea capparoides</i> (roots)	[0.5 - 5]
SU 2169	<i>Ritchiea capparoides</i> (roots)	> 100
SU 2170	<i>Hymenocardia acida</i> (leaves)	[10 - 100]

\*Most active - IC<sub>50</sub> < 10 µg/ml.

**Table 6.** Activity of WRAIR extracts *in vitro* vs. *Trichomonas vaginalis* strains. ATCC 300001 is metronidazole sensitive and ATCC 50143 is resistant. MIC, Minimal Inhibitory Concentration.

Extract	MIC (mg/ml)			
	ATCC 30001		ATCC 50143	
	24h	48h	24h	48h
SU 1863	1.3	0.6	<1.3	0.6
SU 1864	1.3	<1.3	<1.3	<1.3
SU 1865	<1.3	<1.3	<1.3	<1.3
SU 1868	1.3	0.6	1.3	1.3
SU 1870	-	-	0.3	0.3
SU 1873	-	-	1.3	0.6
SU 1876	-	-	<1.3	<1.3
SU 1877	-	-	<1.3	0.6
Metronidazole	-	0.003	-	0.40

**Table 7.** Activity of WRAIR extracts *in vitro* vs. *T. foetus* KV1.

Extract	MIC (mg/ml)	
	24 h	48 h
SU 1863	1.3	-
SU 1864	>1.3	-
SU 1865	>1.3	-
SU 1866	1.3	1.3
SU 1867	>1.3	>1.3
SU 1869	>1.3	1.3
SU 1872	>1.3	1.3
SU 1873	1.3	-
SU 1874	0.6	0.3
SU 1875	>1.3	1.3
SU 1878	1.3	1.3
SU 1879	1.3	0.6
SU 1880	>1.3	1.3
SU 1881	>1.3	1.3
SU 1882	1.3	1.3
SU 1883	>1.3	1.3
SU 1884	1.3	1.3
SU 1887	> 1.3	-
SU 1889	1.3	-
SU 1890	> 1.3	-
SU 1891	>1.3	1.3
SU 1892	>1.3	>1.3
SU 1893	1.3	1.3
SU 1894	>1.3	>1.3
SU 1895	0.63	0.63
SU 1896	0.31	-
SU 1898	>1.3	-
SU 1899	1.3	1.3
SU 1900	>1.3	>1.3
SU 1901	>1.3	>1.3
SU 1902	1.3	1.3
Metronidazole	-	0.003

**Table 8.** Most active WRAIR extracts vs. Trichomonads (MIC  $\leq$  0.6 mg/ml)

<b>Lab Number</b>	<b>Plant Name</b>	<b>Extract</b>
*SU 1863	<i>Aspilia africana</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1868	<i>Combretum dulchipetalim</i>	MeOH
*SU 1870	<i>Combretum dulchipetalim</i>	Aq.
*SU 1873	<i>Enantia chlorontha</i>	MeOH
*SU 1874	<i>Hoslundia opposita</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1877	<i>Mormodica charanta</i>	CH <sub>2</sub> Cl <sub>2</sub>
SU 1879	<i>Phyllanthus amarus</i>	Aq.
SU 1895	<i>Cleistopholis patent</i>	CH <sub>2</sub> Cl <sub>2</sub>

\* Also active vs. trypanosomes